Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead Sciences

Is Gilead Sciences Still a Buy Post COVID-19?

Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…

StockNews.com

Gilead Sciences Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Check Out What Whales Are Doing With GILD

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022

Upgrades

Benzinga

U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Reuters

Gilead Sciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

What Are Whales Doing With Gilead Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Upgrades

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

1 Biotech Stock Investors Will Want to Buy This Week

Gilead Sciences (GILD), a biopharmaceutical company, reported strong demand across its HIV portfolio and raised its full-year guidance. Given the company’s robust profitability and discounted valuation, we think it could be wise to buy the stock now. Read on….

StockNews.com

Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups

Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.

Reuters

Direct-acting antivirals can cure hepatitis C and prisons are now leading efforts to eliminate the virus

While most medical attention has been on COVID, work has been underway to eliminate another viral disease, hepatitis C.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Gilead Sciences Whale Trades For July 14

Benzinga

Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues

Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection.

Benzinga

Traders See Bumpy Road Ahead For Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

Benzinga

Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market capitalization of $74.42 billion.

Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market capitalization of $75.20 billion.

Benzinga

Where Gilead Sciences Stands With Analysts

Over the past 3 months, 11 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ: GILD) reported firs

Benzinga

Recap: Gilead Sciences Q1 Earnings

Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Benzinga

Gilead Sciences's Earnings Outlook

Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead Sciences will report an earnings per share (EPS) of $1.80.

1 2 3 4 5

People

Tony Zhang

13 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.